Comparative Pharmacology
Head-to-head clinical analysis: ENLON versus EXELON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENLON versus EXELON.
ENLON vs EXELON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
None Documented
None Documented
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor